# A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

> **NCT01019603** · PHASE1 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 30 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Tazarotene
- **DRUG:** Tazaroc Gel

## Key facts

- **NCT ID:** NCT01019603
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-12
- **Primary completion:** 2009-12-20
- **Final completion:** 2009-12-20
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019603, "A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01019603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*